Jupiter Neurosciences Doses First Participant In Its Phase 2a RESET Clinical Study Of JOTROL To Treat Parkinson's Disease

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) has announced that the first participant has been dosed in its Phase 2a RESET clinical trial for JOTROL™, aimed at treating Parkinson's disease. This milestone signifies the progression of JOTROL™ into clinical evaluation, with the RESET study designed to assess its safety, tolerability, pharmacokinetics, and biomarker effects in a multicenter, randomized, double-blind, placebo-controlled format.